336 related articles for article (PubMed ID: 26911572)
1. Protective efficacy of a recombinant Newcastle disease virus expressing glycoprotein of vesicular stomatitis virus in mice.
Zhang M; Ge J; Li X; Chen W; Wang X; Wen Z; Bu Z
Virol J; 2016 Feb; 13():31. PubMed ID: 26911572
[TBL] [Abstract][Full Text] [Related]
2. Recombinant adenovirus expressing vesicular stomatitis virus G proteins induce both humoral and cell-mediated immune responses in mice and goats.
Xue X; Yu Z; Jin H; Liang L; Li J; Li X; Wang Y; Cui S; Li G
BMC Vet Res; 2021 Jan; 17(1):36. PubMed ID: 33461549
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of attenuated VSVs with mutated M or/and G proteins as vaccine vectors.
Fang X; Zhang S; Sun X; Li J; Sun T
Vaccine; 2012 Feb; 30(7):1313-21. PubMed ID: 22222871
[TBL] [Abstract][Full Text] [Related]
4. A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection.
Foley HD; McGettigan JP; Siler CA; Dietzschold B; Schnell MJ
Proc Natl Acad Sci U S A; 2000 Dec; 97(26):14680-5. PubMed ID: 11114165
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Antibody Interactions with the G Protein of Vesicular Stomatitis Virus Indiana Strain and Other Vesiculovirus G Proteins.
Munis AM; Tijani M; Hassall M; Mattiuzzo G; Collins MK; Takeuchi Y
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232190
[TBL] [Abstract][Full Text] [Related]
6. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1.
Rose NF; Roberts A; Buonocore L; Rose JK
J Virol; 2000 Dec; 74(23):10903-10. PubMed ID: 11069984
[TBL] [Abstract][Full Text] [Related]
7. Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.
Braxton CL; Puckett SH; Mizel SB; Lyles DS
J Virol; 2010 Apr; 84(7):3552-61. PubMed ID: 20089648
[TBL] [Abstract][Full Text] [Related]
8. Xenoantigen-Dependent Complement-Mediated Neutralization of Lymphocytic Choriomeningitis Virus Glycoprotein-Pseudotyped Vesicular Stomatitis Virus in Human Serum.
Pipperger L; Koske I; Wild N; Müllauer B; Krenn D; Stoiber H; Wollmann G; Kimpel J; von Laer D; Bánki Z
J Virol; 2019 Sep; 93(18):. PubMed ID: 31243134
[TBL] [Abstract][Full Text] [Related]
9. Development of a micro-neutralization assay for ebolaviruses using a replication-competent vesicular stomatitis hybrid virus and a quantitative PCR readout.
Lee SS; Phy K; Peden K; Sheng-Fowler L
Vaccine; 2017 Oct; 35(41):5481-5486. PubMed ID: 28427845
[TBL] [Abstract][Full Text] [Related]
10. Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses.
Publicover J; Ramsburg E; Rose JK
J Virol; 2004 Sep; 78(17):9317-24. PubMed ID: 15308726
[TBL] [Abstract][Full Text] [Related]
11. Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle.
Mackett M; Yilma T; Rose JK; Moss B
Science; 1985 Jan; 227(4685):433-5. PubMed ID: 2981435
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and efficacy of immunodeficiency virus-like particles pseudotyped with the G protein of vesicular stomatitis virus.
Kuate S; Stahl-Hennig C; Stoiber H; Nchinda G; Floto A; Franz M; Sauermann U; Bredl S; Deml L; Ignatius R; Norley S; Racz P; Tenner-Racz K; Steinman RM; Wagner R; Uberla K
Virology; 2006 Jul; 351(1):133-44. PubMed ID: 16616946
[TBL] [Abstract][Full Text] [Related]
13. Epitope mapping by deletion mutants and chimeras of two vesicular stomatitis virus glycoprotein genes expressed by a vaccinia virus vector.
Keil W; Wagner RR
Virology; 1989 Jun; 170(2):392-407. PubMed ID: 2471352
[TBL] [Abstract][Full Text] [Related]
14. Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle.
Majid AM; Ezelle H; Shah S; Barber GN
J Virol; 2006 Jul; 80(14):6993-7008. PubMed ID: 16809305
[TBL] [Abstract][Full Text] [Related]
15. SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector.
Kapadia SU; Simon ID; Rose JK
Virology; 2008 Jun; 376(1):165-72. PubMed ID: 18396306
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a recombinant Newcastle disease virus expressing the glycoprotein of bovine ephemeral fever virus.
Zhang M; Ge J; Wen Z; Chen W; Wang X; Liu R; Bu Z
Arch Virol; 2017 Feb; 162(2):359-367. PubMed ID: 27757685
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of propagation-restricted vesicular stomatitis virus encoding Ebola virus glycoprotein in guinea pigs.
Locher S; Schweneker M; Hausmann J; Zimmer G
J Gen Virol; 2018 Jul; 99(7):866-879. PubMed ID: 29869979
[TBL] [Abstract][Full Text] [Related]
18. Cytolytic T lymphocytes from the BALB/c-H-2dm2 mouse recognize the vesicular stomatitis virus glycoprotein and are restricted by class II MHC antigens.
Browning MJ; Huang AS; Reiss CS
J Immunol; 1990 Aug; 145(3):985-94. PubMed ID: 1695651
[TBL] [Abstract][Full Text] [Related]
19. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
[TBL] [Abstract][Full Text] [Related]
20. mRNA cap methylation influences pathogenesis of vesicular stomatitis virus in vivo.
Ma Y; Wei Y; Zhang X; Zhang Y; Cai H; Zhu Y; Shilo K; Oglesbee M; Krakowka S; Whelan SP; Li J
J Virol; 2014 Mar; 88(5):2913-26. PubMed ID: 24371058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
